ClinicalTrials.gg
RecruitingNCT06851338Updated Feb 28, 2025

Pediatric Down Syndrome Post-Approval Study

An interventional study of Hypoglossal Nerve Stimulation in Pediatric Obstructive Sleep Apnea and Down Syndrome (DS), sponsored by Inspire Medical Systems, Inc.. Recruiting at 6 sites in United States. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Inspire Medical Systems, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Down Syndrome with a site in United States — 47 open to participants now, 55 under way, 4 of them phase 3. Down Syndrome · United States.

Planned enrollment
40th of 131
60 · median 40
Started
2025
with 9 others
No phase
82 of 205
19 open now
Primary completion
2030-05
later than 47 of 54 live
Registered
180th of 205
by date

Among the 205 studies in Down Syndrome with a site in United States, this one is the 40th largest by planned enrollment of the 131 interventional ones that give a count, is one of 10 that started in 2025, is one of 82 with no phase, reaches primary completion later than 47 of the 54 other live ones, and was the 180th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

47 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Down Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Post Approval research study is to assess ongoing safety and effectiveness of the Inspire therapy in adolescents and young adults (age 13-18) with Down syndrome and severe sleep apnea. The objective of the study is to provide an ongoing safety and effectiveness assessment of the Inspire UAS System in the Pediatric Down syndrome population.

Read the detailed description

This is a multi-center, prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow sixty (60) adolescents (13 - 18), with Down Syndrome and severe sleep apnea for 5-years after undergoing implant of the Inspire Upper Airway Stimulation (UAS) system. The objective of the study is to provide an ongoing safety and effectiveness assessment of the Inspire UAS System in the Pediatrics Down Syndrome population.

Prior to implant subjects will be required to meet eligibility criteria that is based on an in-lab PSG, surgical consultation and drug induced sleep endoscopy, as well as other assessments. Subjects will also complete quality of life questionnaires.

During the 5-year follow-up period, data will be collected at the time of implant, and at multiple follow-up visits through five years post-implant. At each of these visits, safety information (adverse events), sleep data, therapy usage, and quality of life will be collected.

A total of sixty (60) subjects with even distribution across the age range will be implanted at a minimum of five (5) clinical centers in the US.

Subjects will conclude their participation in the study at the end of their 5 year follow-up visit.

03

Conditions studied

  • Pediatric Obstructive Sleep Apnea
  • Down Syndrome (DS)

Keywords

  • Pediatrics
  • OSA
  • Down Syndrome
  • Pediatrics OSA
  • Obstructive Sleep Apnea
  • Long-term follow-up
  • Post Approval Study
  • PAS
04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has been diagnosed with Down syndrome;
  2. Patient is 13-18 years of age;
  3. Patient has been diagnosed with severe obstructive sleep apnea, with an AHI of ≥ 10 and ≤ 50 based on a recent (within 6 months of enrollment) qualified in-lab sleep study (PSG);
  4. Patient has documented failure of, or intolerance to, positive airway pressure therapies (such as CPAP or BiPAP) despite attempts to improve compliance;
  5. Patient is for, or not effectively treated by, adenotonsillectomy;
  6. Treatment of patient's OSA has followed standard of care in considering all other alternative/adjunctive therapies;
  7. Patient, and their parents/guardians, is willing to have stimulation hardware permanently implanted, and be willing to participate in follow-up visits, postoperative in-lab sleep studies (PSGs), and questionnaire completion.

Exclusion criteria

Exclusion Criteria:

  1. Patient's recent PSG (within 6 months of enrollment) reports central + mixed apneas > 25% of the total apnea-hypopnea index (AHI);
  2. Patient has any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate;
  3. Patient has any condition or procedure that has compromised neurological control of the upper airway;
  4. Patient, or their parent/guardian, is unable or does not have the necessary assistance to operate the patient remote;
  5. Patient is pregnant or plans to become pregnant;
  6. Patient has an implantable device that may be susceptible to unintended interaction with the Inspire system;
  7. Patient will require magnetic resonance imaging (MRI) other than what is specified in the MR conditional labeling;
  8. Patient has a terminal illness with of less than 12 months;
  9. Any other reason the investigator deems the patient is unfit for participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Pediatric subjects with Down syndrome undergoing Inspire UAS Implant

    This study is a prospective, multi-center, single-arm study of pediatric subjects (age 13-18) with Down syndrome who are undergoing implant of the Inspire Upper Airway Stimulation (UAS) system for the treatment of severe obstructive sleep apnea (OSA).

    Device: Hypoglossal Nerve Stimulation

Interventions

  • DeviceHypoglossal Nerve Stimulation

    Implant of Inspire Upper Airway Stimulation (UAS) system for treatment of obstructive sleep apnea (OSA) in the pediatric down syndrome population

    Also known as: Inspire Upper Airway Stimulation (UAS) System

06

What researchers measure

Primary outcomes

  1. Safety Outcome Measure - Procedure and Device-related Adverse events

    Procedure-related and Device-related adverse events will be summarized by seriousness and severity. No formal hypothesis will be tested.

    Time frame: Implant through 5 Years

  2. Effectiveness Outcome Measure - Comparison of Baseline and Annual Apnea-Hypopnea Index (AHI)

    The AHI will be collected at each sleep study. This effectiveness measure will be reported as a comparison of baseline and annual (1-5 year) AHI. Descriptive statistics will be used to analyze this data. No formal hypothesis will be tested.

    Time frame: Baseline and Annually through 5 Years post-implant

Secondary outcomes

  1. Effectiveness Outcome Measure - Comparison of Baseline, 6 month, and Annual Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD)

    The ESS-CHAD will be completed at baseline, as well as 6 months and annually (1-5 years) post-implant. The ESS-CHAD score at baseline compared to the ESS-CHAD score at each annual study visit will be reported. Descriptive statistics will be used to analyze this data. No formal hypothesis will be tested.

    Time frame: Baseline, 6 months, and annually through 5-year post-implant

  2. Effectiveness Outcome Measure - Comparison of Baseline and Annual Percent Time Oxygen Saturation < 90% (T90)

    Descriptive statistics will be used to analyze this data. No formal hypothesis will be tested.

    Time frame: Baseline and Annually through 5-year post-implant

  3. Effectiveness Outcome Measure - Comparison of Baseline and Annual Oxygen Desaturation Index (ODI)

    The ODI will be collected during each sleep study. This effectiveness measure will be reported as a comparison of baseline and annual (1-5 year) ODI. Descriptive statistics will be used to analyze this data. No formal hypothesis will be tested.

    Time frame: Baseline and Annually through 5 years post-implant

Other outcomes

  1. Ancillary Outcome Measure - Therapy Usage

    Therapy usage, reported as hours per week and averaged into hours per night, will be used to quantify device use and adherence over time (6M, annually 1-5 years). Descriptive statistics will be used to analyze this data. No formal hypothesis will be tested.

    Time frame: 6 Months and Annually through 5 years post-implant

07

Study locations

1 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for May 2030, 63 months later.

Of 165 interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 35. This study's planned 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 28, 2025
StartEst.
Feb 2025
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06851338
Lead sponsor
Inspire Medical Systems, Inc.
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Feb 2025 (estimated)
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Feb 28, 2025

Study contacts

Angela Chapin, Sr. Clinical Study Manager
Contact
angelachapin@inspiresleep.com
763.392.7222
Gwen Gimmestad, VP Clinical
Contact
gwengimmestad@inspiresleep.com
763.392.9966

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion